Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology
Shots:
- TetraGenetics to receive $25M upfront- $248M milestones as contingent payments- FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders
- The focus of the agreement is to develop non-opioid therapies with advancement of mAbs targeting ion channels utilizing TetraExpress technology for the treatment of pain conditions
- TetraExpress technology is an Ab discovery platform for developing biologics targeting ion channel for autoimmune diseases and pain
Ref: Imbrium Therapeutics | Image: MassBio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com